OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III
Executive Summary
OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.